Based on the measurements of operating efficiency obtained from AstraZeneca PLC's historical financial statements, AstraZeneca PLC ADR may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, AstraZeneca PLC's Retained Earnings are very stable compared to the past year. As of the 1st of December 2024, Accounts Payable is likely to grow to about 6.1 B, while Property Plant And Equipment Net is likely to drop about 6.8 B. Key indicators impacting AstraZeneca PLC's financial strength include:
Investors should never underestimate AstraZeneca PLC's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor AstraZeneca PLC's cash flow, debt, and profitability to make informed and accurate decisions about investing in AstraZeneca PLC ADR.
Net Income
3.47 Billion
AstraZeneca
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Invested Capital
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Tangible Asset Value
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Dividends Paid
Other Cashflows From Investing Activities
Change To Account Receivables
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Change To Operating Activities
Issuance Of Capital Stock
Stock Based Compensation
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Total Liab
Total Current Assets
Short Term Debt
Other Stockholder Equity
Capital Stock
Common Stock
Other Assets
Intangible Assets
Other Liab
Long Term Debt
Good Will
Other Current Assets
Property Plant Equipment
Current Deferred Revenue
Net Receivables
Common Stock Total Equity
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Noncontrolling Interest In Consolidated Entity
Additional Paid In Capital
Net Tangible Assets
Long Term Investments
Short Long Term Debt
Deferred Long Term Liab
Long Term Debt Total
Capital Surpluse
Capital Lease Obligations
Net Invested Capital
Net Working Capital
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Cost Of Revenue
Net Income Applicable To Common Shares
Minority Interest
Selling And Marketing Expenses
Net Income From Continuing Ops
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past AstraZeneca PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AstraZeneca PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in AstraZeneca PLC's assets may result in an increase in income on the income statement.
AstraZeneca PLC competes with Novartis, GlaxoSmithKline PLC, Roche Holding, Bristol Myers, and Sanofi ADR. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 83100 people.
Foreign Associates
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.
AstraZeneca PLC ADR is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.51 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for AstraZeneca PLC ADR is roughly 1.96 . At this time, AstraZeneca PLC's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.
AstraZeneca PLC ADR Systematic Risk
AstraZeneca PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AstraZeneca PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on AstraZeneca PLC ADR correlated with the market. If Beta is less than 0 AstraZeneca PLC generally moves in the opposite direction as compared to the market. If AstraZeneca PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AstraZeneca PLC ADR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AstraZeneca PLC is generally in the same direction as the market. If Beta > 1 AstraZeneca PLC moves generally in the same direction as, but more than the movement of the benchmark.
AstraZeneca PLC Thematic Clasifications
AstraZeneca PLC ADR is part of Compulsion investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Addiction driven consumer products and services. Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol
This theme covers Addiction driven consumer products and services. Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. Get More Thematic Ideas
Today, most investors in AstraZeneca PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AstraZeneca PLC's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of AstraZeneca PLC growth as a starting point in their analysis.
AstraZeneca PLC December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of AstraZeneca PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AstraZeneca PLC ADR. We use our internally-developed statistical techniques to arrive at the intrinsic value of AstraZeneca PLC ADR based on widely used predictive technical indicators. In general, we focus on analyzing AstraZeneca Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AstraZeneca PLC's daily price indicators and compare them against related drivers.
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.034
Dividend Share
2.97
Earnings Share
2.08
Revenue Per Share
2.7424
Quarterly Revenue Growth
0.18
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.